Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume 98, Issue 5 , Pages 261-267 , May 2004

Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether

Received 18 September 2003 ,Revised 1 November 2003 ,Accepted 12 November 2003.

References 

  1. Berninger E, Karlsson KK, Alvan G. Quinine reduces the dynamic range of the human auditory system. Acta Otolaryngol. 1998;118:46–51
  2. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, et al. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. 1994;51:251–259
  3. Brewer TG, Peggins JO, Grate SJ, Petras JM, Levine BS, Weina PJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 1994;88:33–36
  4. Claessen FA, van Boxtel CJ, Perenboom RM, Tange RA, Weststeijn JC, Kager PA. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop. Med. Int. Health. 1998;6:482–489
  5. Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemesinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv. Pharmacol. 1997;37:253–297
  6. Dayan AD. Neurotoxicity and artemesinin compounds do the observations in animals justify limitation of clinical use?. Med Trop. (Mars). 1998;583:32–37
  7. Fusetti M, Eibenstein A, Corridore V, Hueck S, Chiti-Batelli S. [Mefloquine and ototoxicity: a report of 3 cases] [Italian]. Clin. Ter. 1999;150:379–382
  8. Genovese RF, Newman DB, Brewer TG. Behavioral and neural toxicity of the artemesinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol. Biochem. Behav. 2000;67:37–44
  9. Hadi U, Nuwayhid N, Hasbini AS. Chloroquine ototoxicity: an idiosyncratic phenomenon. Otolaryngol. Head Neck Surg. 1996;114:491–493
  10. Hien TT, Turner GD, Mai NT, Phu NH, Bethell D, Blakemore WF, et al. Neuropathological assessment of artemether-treated severe malaria. Lancet. 2003;362:295–296
  11. Hoffman SL. Artemether in severe malaria—Still too many deaths. N. Engl. J. Med. 1996;335:124–126
  12. Karbwang J, Bangchang KN, Thanavibul A, Wattanakoon Y, Harinasuta T. Quinine toxicity when given with doxycycline and mefloquine. Southeast Asian J. Trop. Med. Public Health. 1994;25:397–400
  13. Karlsson KK, Hellgren U, Alvan G, Rombo L. Audiometry as a possible indicator of quinine plasma concentration during treatment of malaria. Trans. R. Soc. Trop. Med. Hyg. 1994;84:765–767
  14. Kissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV, et al. Clinical and neurophysiological study of the effects of multiple doses of artemesinin on brain-stem function in Vietnamese patients. Am. J. Trop. Med. Hyg. 2000;63:48–55
  15. Krause PJ, Lepore T, Sikand VK, Gadbaw J, Burke G, Telford SR, et al. Atovaquone and azithromycin for the treatment of babesiosis. N. Engl. J. Med. 2000;343:1454–1458
  16. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemesinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 1996;60:301–315
  17. Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N. Engl. J. Med. 1997;336:1328
  18. Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus BJ, White NJ. Assessment of the neurotoxicity of parenteral artemesinin derivatives in mice. Am. J. Trop. Med. Hyg. 1998;59:519–522
  19. Nontprasert A, Pukrittayakamee S, Nosten-Bertrand M, Vanijanonta S, White NJ. Studies of the neurotoxicity of oral artemesinin derivatives in mice. Am. J. Trop. Med. Hyg. 2000;62:409–412
  20. Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S, White NJ. Neuropathologic toxicity of artemesinin derivatives in a mouse model. Am. J. Trop. Med. Hyg. 2002;67:423–429
  21. Nontprasert A, Pukrittayakamee S, Prakongpan S, Supanaranond W, Looareesuwan S, White NJ. Assessment of the neurotoxicity of oral dihydroartemesinin in mice. Trans. R. Soc. Trop. Med. Hyg. 2002;96:99–101
  22. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction?. Drug. Saf. 1995;12:370–383
  23. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, et al. Adverse effects in patients with acute falciparum malaria treated with artemesinin derivatives. Am. J. Trop. Med. Hyg. 1999;60:547–555
  24. Roche RJ, Silamut K, Pukrittayakamee S, Looareesuwan S, Molunto P, Boonamrung S, et al. Quinine induces reversible high-tone hearing loss. Br. J. Clin. Pharmacol. 1990;29:780–782
  25. Sowunmi A. Clinical study of cerebral malaria in African children. Afr. J. Med. Sci. 1997;26:9–11
  26. Tange RA, Dreschler WA, Claessen FA, Perenboom RM. Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx. 1997;24:131–136
  27. Toovey S, Jamieson A. Co-artemether has been used in ambulatory treatment of falciparum malaria. BMJ. 2002;324:1585
  28. Utzinger J, Xiao S, N’Goran EK, Bergquist R, Tanner M. The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. 2001;31:1549–1562
  29. Utzinger J, Chollet J, Tu Z, Xiao S, Tanner M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans. R. Soc. Trop. Med. Hyg. 2002;96:318–323
  30. van Vugt M, Angus BJ, Price RN, Mann C, Simpson JA, Poletto C, et al. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2000;62:65–69
  31. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999;41:301–308
  32. White NJ. Neurological dysfunction following malaria: disease- or drug-related?. Clin. Infect. Dis. 2000;30:836
  33. White NJ, Olliaro P. Artemesinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. (Mars.). 1998;58:54–56
  34. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965–1967
  35. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 1999;37:105–125
  36. WHO, 2000. Management of Severe Malaria. A Practical Handbook, second ed. World Health Organization, Geneva.
  37. Xiao S, Tanner M, N’Goran EK, Utzinger J, Chollet J, Bergquist R, et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta. Trop. 2002;82:175–181
  38. Xiao S, Yang Y, You Q, Utzinger J, Guo H, Peiying J, et al. Potential long-term toxicity of repeated orally administered doses of artemether in rats. Am. J. Trop. Med. Hyg. 2002;66:30–34

PII: S0035-9203(03)00091-9

doi: 10.1016/j.trstmh.2003.11.001

Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume 98, Issue 5 , Pages 261-267 , May 2004

Article Tools

* Image Usage & Resolution